MarketOne Video Interview with CEO Christopher J. Moreau – Algernon Pharmaceuticals is the First to Investigate DMT as a Treatment for Stroke

Christopher Moreau, CEO and Director of Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF) highlights how DMT represents a potential new way of thinking about treatment for stroke.

Algernon Pharmaceuticals is a Canadian clinical-stage drug development company investigating multiple drugs with global unmet medical needs.